Related Experiment Videos
Bleeding time and antiplatelet agents in normal volunteers
E M Pogliani1, C Fowst, R Bregani
1Department of Internal Medicine, S. Gerardo Hospital, Monza, Italy.
International Journal of Clinical & Laboratory Research
|January 1, 1992
Summary
This study compared antiplatelet drugs: acetylsalicylic acid (ASA), ticlopidine, and indobufen. Ticlopidine significantly prolonged bleeding time longer than ASA and indobufen, even 48 hours after treatment cessation.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Research
Background:
- Antiplatelet agents are crucial for preventing arterial thrombosis.
- These agents are known to increase bleeding time.
- Understanding comparative effects on bleeding is vital for patient safety.
Purpose of the Study:
- To compare the effects of acetylsalicylic acid (ASA), ticlopidine, and indobufen on bleeding time.
- To evaluate the duration of action of these antiplatelet drugs on bleeding.
Main Methods:
- A randomized cross-over study involving 12 healthy subjects.
- Four treatments administered sequentially: ASA (300mg daily, 500mg BID), ticlopidine (250mg BID), and indobufen (200mg BID).
- Bleeding time measured using a Surgicut device at multiple time points before, during, and after treatment periods with a 15-day washout.
Main Results:
- Both doses of ASA and indobufen rapidly prolonged bleeding time.
- Indobufen's effect diminished quickly post-treatment, unlike ASA.
- Ticlopidine prolonged bleeding time after 24 hours, with a significantly higher mean value than ASA and indobufen after 7 days.
- This prolonged bleeding time with ticlopidine persisted for 48 hours post-treatment.
Conclusions:
- Ticlopidine exhibits a more sustained prolongation of bleeding time compared to ASA and indobufen.
- The delayed onset and prolonged effect of ticlopidine on bleeding time warrant consideration in clinical practice.
- Comparative analysis of antiplatelet agents is essential for optimizing therapeutic strategies and managing bleeding risks.